Latest Conference Articles

MRD-Guided Combination Treatment Appears Feasible in Patients With a Form of Relapsed/Refractory Leukemia

MRD-Guided Combination Treatment Appears Feasible in Patients With a Form of Relapsed/Refractory Leukemia

December 11th 2021, 10:00pm

American Society of Hematology Annual Meeting

Using the presence of minimal residual disease to direct Imbruvica plus Venclexta treatment appears to be a feasible option for patients with relapsed/refractory chronic lymphocytic leukemia.

Imbruvica, Venclexta Combo Offers Chemotherapy-Free Regimen for Patients with CLL

Imbruvica, Venclexta Combo Offers Chemotherapy-Free Regimen for Patients with CLL

December 11th 2021, 6:34pm

American Society of Hematology Annual Meeting

Recent results demonstrated durable responses and no new side effects for Venclexta plus Imbruvica in pretreated chronic lymphocytic leukemia.

CAR-T Cell Therapy Bests Standard of Care in Health-Related Quality of Life for Patients With Lymphoma

CAR-T Cell Therapy Bests Standard of Care in Health-Related Quality of Life for Patients With Lymphoma

December 11th 2021, 4:00pm

American Society of Hematology Annual Meeting

Patients with large B-cell lymphoma tended to have better quality of life that continued to improve over time after receiving Breyzani compared to those given standard of care.

Lynparza After Chemo May Not Greatly Impact Quality of Life in High-Risk Early Breast Cancer Subset

Lynparza After Chemo May Not Greatly Impact Quality of Life in High-Risk Early Breast Cancer Subset

December 11th 2021, 3:00pm

SABCS

Although patients treated with Lynparza after chemotherapy may experience side effects such as fatigue and nausea/vomiting, these symptoms resolved after treatment was completed in patients with high-risk early breast cancer.

Triplet Regimen Extends Time Before Brain, Spinal Cord Metastases Worsen in Patients With Breast Cancer

Triplet Regimen Extends Time Before Brain, Spinal Cord Metastases Worsen in Patients With Breast Cancer

December 10th 2021, 10:00pm

SABCS

A three-drug regimen was shown to lengthen the amount of time before cancer progressed to the central nervous system — known as central nervous system progression-free survival — in certain patients with breast cancer.

Dose Reduction of Xpovio Improves Safety and Optimizes Patient Outcomes in Myeloma

Dose Reduction of Xpovio Improves Safety and Optimizes Patient Outcomes in Myeloma

December 10th 2021, 8:00pm

American Society of Hematology Annual Meeting

In recent trial results, a dose reduction of Xpovio (selinexor) was associated with longer progression-free survival and duration of response while also reducing side effects in patients with multiple myeloma.

Experimental Drug Plus Chemo Boosts Survival in HER2-Positive Metastatic Breast Cancer

Experimental Drug Plus Chemo Boosts Survival in HER2-Positive Metastatic Breast Cancer

December 10th 2021, 5:00pm

SABCS

The use of pyrotinib — an experimental drug — plus the chemotherapy capecitabine extended survival compared with Tykerb and capecitabine among patients with pretreated HER2-positive metastatic breast cancer.

Novel Drug Elicits Favorable Outcomes in Advanced, Metastatic TNBC

Novel Drug Elicits Favorable Outcomes in Advanced, Metastatic TNBC

December 10th 2021, 2:00pm

SABCS

Early-phase study results showed that treatment with a novel drug elicits promising outcomes in patients with advanced or metastatic triple-negative breast cancer.

Immunotherapy Before Surgery May ‘Increase the Chances’ Patients Are Cured of TNBC

Immunotherapy Before Surgery May ‘Increase the Chances’ Patients Are Cured of TNBC

December 9th 2021, 10:00pm

SABCS

Clinical trial results show that adding Keytruda to chemotherapy prior to surgery for triple-negative breast cancer can improve outcomes and hopefully “increase the chances for patients to be cured,” according to an expert.

Study Confirms Adding Ibrance to Endocrine Therapy May Not Improve Outcomes in Early Breast Cancer

Study Confirms Adding Ibrance to Endocrine Therapy May Not Improve Outcomes in Early Breast Cancer

December 8th 2021, 10:00pm

SABCS

The addition of Ibrance to endocrine therapy was not associated with preventing disease recurrence in patients with hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative early breast cancer, according to final results of the phase 3 PALLAS trial.

Medication Used to Treat Diabetes Fails to Improve Breast Cancer Outcomes

Medication Used to Treat Diabetes Fails to Improve Breast Cancer Outcomes

December 8th 2021, 4:00pm

SABCS

Researchers hypothesized that metformin — a medication that helps lower insulin levels in patients with diabetes and is associated with inducing weight loss — might improve breast cancer outcomes.

Novel Drug Has Potential to ‘Become New Standard of Care’ in Advanced, ER-Positive Breast Cancer

Novel Drug Has Potential to ‘Become New Standard of Care’ in Advanced, ER-Positive Breast Cancer

December 8th 2021, 2:00pm

SABCS

The use of elacestrant, an investigational therapy, elicited a 30% reduction in the risk of disease progression or death compared with standard of care in a group of patients with estrogen receptor (ER)–positive, HER2-negative metastatic breast cancer.

Novel Drug Combo Doubles Progression-Free Survival in HER2-Negative Metastatic Breast Cancer

Novel Drug Combo Doubles Progression-Free Survival in HER2-Negative Metastatic Breast Cancer

December 7th 2021, 10:00pm

SABCS

Ibrance plus Faslodex improved progression-free survival in certain patients with metastatic breast cancer, compared with those who continued to receive an aromatase inhibitor.

Black Women With Breast Cancer Have a Higher Risk of Developing Lymphedema Than White Women

Black Women With Breast Cancer Have a Higher Risk of Developing Lymphedema Than White Women

December 7th 2021, 4:00pm

SABCS

Black race is associated with a 3.5-fold increased incidence of lymphedema in women with breast cancer treated with axillary lymph node dissection and radiotherapy, according to recent data.

Educated Patient® Breast Cancer Summit Outside of Therapy Session: November 13, 2021

Educated Patient® Breast Cancer Summit Outside of Therapy Session: November 13, 2021

November 13th 2021, 2:02pm

2021 Educated Patient Summits

View the full CURE Educated Patient Breast Cancer Summit Outside of Therapy Session on demand.

Educated Patient® Breast Cancer Summit Novel Therapies Session: November 13, 2021

Educated Patient® Breast Cancer Summit Novel Therapies Session: November 13, 2021

November 13th 2021, 2:01pm

2021 Educated Patient Summits

View the full CURE Educated Patient Breast Cancer Summit Novel Therapies Session on demand.

Educated Patient® Breast Cancer Summit Multi-Disciplinary Approaches to Early-Stage Breast Cancer Session: November 13, 2021

Educated Patient® Breast Cancer Summit Multi-Disciplinary Approaches to Early-Stage Breast Cancer Session: November 13, 2021

November 13th 2021, 2:00pm

2021 Educated Patient Summits

View the full CURE Educated Patient Breast Cancer Summit Multi-Disciplinary Approaches to Early-Stage Breast Cancer Session on demand.

Educated Patient® Kidney Cancer Summit: October 24, 2021

Educated Patient® Kidney Cancer Summit: October 24, 2021

October 24th 2021, 3:00pm

2021 Educated Patient Summits

View the full CURE Educated Patient Kidney Cancer Summit on demand.

Educated Patient® Multiple Myeloma Summit in Partnership with Sylvester Comprehensive Cancer Center, University of Miami

Educated Patient® Multiple Myeloma Summit in Partnership with Sylvester Comprehensive Cancer Center, University of Miami

October 2nd 2021, 2:00pm

2021 Educated Patient Summits

View the full CURE® Educated Patient® Multiple Myeloma Summit in Partnership with Sylvester Comprehensive Cancer Center, University of Miami on demand.

Educated Patient® MPN Summit: August 28, 2021

Educated Patient® MPN Summit: August 28, 2021

August 28th 2021, 3:00pm

2021 Educated Patient Summits

View the full CURE Educated Patient MPN Summit on demand.

Educated Patient® Lung Cancer Summit Basics of Lung Cancer Session: August 14, 2021

Educated Patient® Lung Cancer Summit Basics of Lung Cancer Session: August 14, 2021

August 14th 2021, 5:00pm

2021 Educated Patient Summits

View the full CURE Educated Patient Lung Cancer Summit on demand.

Educated Patient® Lung Cancer Summit Targeted Treatment Session: August 14, 2021

Educated Patient® Lung Cancer Summit Targeted Treatment Session: August 14, 2021

August 14th 2021, 5:00pm

2021 Educated Patient Summits

View the full CURE Educated Patient Lung Cancer Summit on demand.

Educated Patient® Lung Cancer Summit Looking Ahead Session: August 14, 2021

Educated Patient® Lung Cancer Summit Looking Ahead Session: August 14, 2021

August 14th 2021, 5:00pm

2021 Educated Patient Summits

View the full CURE Educated Patient Lung Cancer Summit on demand.

Educated Patient® Leukemia Summit: July 31, 2021

Educated Patient® Leukemia Summit: July 31, 2021

August 3rd 2021, 3:38pm

2021 Educated Patient Summits

View the full CURE Educated Patient Leukemia Summit on demand.

Educated Patient® Skin Cancer Summit: June 26, 2021

Educated Patient® Skin Cancer Summit: June 26, 2021

June 26th 2021, 2:00pm

2021 Educated Patient Summits

View the full CURE Educated Patient Skin Cancer Summit on demand.

Imfinzi May Contribute to Long-Term Survival Improvements in Unresectable Non-Small Cell Lung Cancer

Imfinzi May Contribute to Long-Term Survival Improvements in Unresectable Non-Small Cell Lung Cancer

June 7th 2021, 1:00pm

ASCO Annual Meeting

The long-term follow-up data, according to one of the study’s authors from the Sarah Cannon Cancer Institute, demonstrate “a new benchmark for the standard of care” in the treatment of patients with unresectable stage 3 non-small cell lung cancer.

Aumolertinib Improves Survival in Advanced Non-Small Cell Lung Cancer

Aumolertinib Improves Survival in Advanced Non-Small Cell Lung Cancer

June 7th 2021, 12:00pm

ASCO Annual Meeting

Treatment with aumolertinib was associated with prolonged survival in patients with advanced non-small cell lung cancer.

Abecma Continues to Improve Survival in Heavily Pretreated Patients With Multiple Myeloma

Abecma Continues to Improve Survival in Heavily Pretreated Patients With Multiple Myeloma

June 6th 2021, 8:00pm

ASCO Annual Meeting

After long-term follow-up, the CAR-T cell therapy still boosted survival outcomes in patients with relapsed/refractory multiple myeloma, regardless of the number of prior lines of therapy received.

Retevmo Shows Improvement for Previously Treated Patients With Non-Small Cell Lung Cancer

Retevmo Shows Improvement for Previously Treated Patients With Non-Small Cell Lung Cancer

June 6th 2021, 7:00pm

ASCO Annual Meeting

Previously treated patients with non-small cell lung cancer tended to have better responses with Retevmo than they did with prior treatments.

Novel Combo Therapy Shows Promise in Certain Patients With Non-Hodgkin Lymphoma

Novel Combo Therapy Shows Promise in Certain Patients With Non-Hodgkin Lymphoma

June 6th 2021, 5:00pm

ASCO Annual Meeting

Treatment with a novel combination therapy was associated with increased efficacy among patients with aggressive relapsed or refractory B-cell non-Hodgkin lymphoma and was also well tolerated.